Notice: This company has been marked as potentially delisted and may not be actively trading. NYSE:NVTA Invitae (NVTA) Stock Price, News & Analysis Add Share Share Stock Analysis Stock AnalysisHeadlinesInsider TradesOwnershipSustainabilityTrends About Invitae Stock (NYSE:NVTA) 30 days 90 days 365 days Advanced Chart Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Invitae alerts:Sign Up Key Stats Today's Range$0.0003▼$0.000350-Day Range N/A52-Week Range$0.02▼$0.02Volume75 shsAverage Volume23.72 million shsMarket Capitalization$80,103.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Read More… New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address NVTA Stock News HeadlinesInvitae Corp (OTC:NVTA) Stock, Insider Trading ActivityOctober 3, 2024 | benzinga.comInvitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy PatientsJuly 22, 2024 | finance.yahoo.com2024 Election Year Stocks: Uncover Hidden Gems!In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.November 21, 2024 | Darwin (Ad)Invitae's $239 million sale to Labcorp approved by Bankruptcy CourtMay 7, 2024 | bizjournals.comLabcorp to acquire Invitae in strategic dealApril 28, 2024 | msn.comLabcorp to acquire Invitae assets for $239 millionApril 26, 2024 | uk.investing.comLabcorp wins $239M bid for bankrupt InvitaeApril 26, 2024 | bizjournals.comLabcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae DealApril 25, 2024 | msn.comSee More Headlines NVTA Stock Analysis - Frequently Asked Questions How were Invitae's earnings last quarter? Invitae Co. (NYSE:NVTA) released its quarterly earnings data on Tuesday, May, 9th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.04. Invitae's revenue for the quarter was down 5.1% on a year-over-year basis. When did Invitae IPO? Invitae (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. What other stocks do shareholders of Invitae own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invitae investors own include NVIDIA (NVDA), Block (SQ), Tesla (TSLA), Meta Platforms (META), CrowdStrike (CRWD), Teladoc Health (TDOC) and PayPal (PYPL). Company Calendar Last Earnings5/09/2023Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNYSE:NVTA CUSIPN/A CIK1501134 Webwww.invitae.com Phone(628) 213-3369FaxN/AEmployees1,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,106,290,000.00 Net Margins-299.14% Pretax Margin-301.93% Return on Equity-6,100.71% Return on Assets-19.68% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.25 Sales & Book Value Annual Sales$481.58 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book0.00Miscellaneous Outstanding Shares267,010,000Free Float284,373,000Market Cap$80,103.00 OptionableOptionable Beta1.59 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NYSE:NVTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invitae Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invitae With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.